Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 320 ◽  
Author(s):  
Michael S. Gold ◽  
Jim Buttery ◽  
Peter McIntyre
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Case Series ◽  
Vaccine Safety ◽  
Age Group ◽  
Human Papillomavirus Vaccine ◽  
Federally Funded ◽  
Conversion Disorders ◽  
Passive Surveillance System ◽  
Papillomavirus Vaccine

Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

Vaccine Hesitancy and Differential Susceptibility to Media Coverage: A Critical Documentary Led to Substantial Reductions in Human Papillomavirus Vaccine Uptake in Denmark

2021 ◽  
pp. 0272989X2110035
Author(s):  
Maria Knoth Humlum ◽  
Niels Skipper ◽  
Peter Rønø Thingholm
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Media Coverage ◽  
Differential Susceptibility ◽  
Vaccine Uptake ◽  
Vaccine Hesitancy ◽  
Human Papillomavirus Vaccine ◽  
Policy Makers ◽  
Quasi Experimental ◽  
Papillomavirus Vaccine

Objectives To investigate whether negative media coverage of the human papillomavirus (HPV) vaccine led to a decrease in the uptake of the first dose of the HPV vaccine (HPV1) in Denmark and, importantly, whether some groups of individuals were more susceptible to negative media coverage. Methods We measured HPV vaccine uptake of 12-year-old girls born in 2001 to 2004 using Danish administrative data. A quasi-experimental design was employed to assess whether a documentary that was critical of the HPV vaccine and aired in March 2015 affected HPV uptake. Results The documentary led to a quick and substantial decrease in the monthly propensity to vaccinate, which dropped 3 percentage points—or about 50%—in response to the documentary. Responses differed substantially across subgroups, and girls from families with high socioeconomic status (SES) were more susceptible to the negative media coverage. Conclusions Susceptibility to negative media coverage varied substantially across subgroups, highlighting the need for policy makers to appropriately target and differentiate initiatives to improve vaccine compliance rates.

A Case of Myopericarditis and the HPV vaccine

2021 ◽  
Vol 9 (12) ◽  
Author(s):  
Angela Pegram ◽  
Tara Bush
Keyword(s):  
Human Papillomavirus ◽  
Social History ◽  
Hpv Vaccine ◽  
Package Insert ◽  
Human Papillomavirus Vaccine ◽  
T Wave ◽  
Dose Number ◽  
Males And Females ◽  
Artery Disease ◽  
Papillomavirus Vaccine

Introduction: Human Papillomavirus (HPV) is the underlying etiology of numerous cancers and genital warts in both males and females. Vaccines were developed against HPV to prevent transmission and arrest development of cancers caused by the virus. Gardasil 9â is the newest vaccine, covering 9 serotypes of HPV and is recommended by the CDC for both males and females over 9 years of age in a series of vaccinations. Myopericarditis (including myocarditis and pericarditis) is not reported as an adverse reaction in the Gardasil 9â package insert. Case Report A healthy 18-year-old male with no significant past medical or social history received dose number 3 of HPV vaccine at his physician’s office. Within 24 hours, he developed chills and a fever (normal HPV reactions) and then recovered without sequelae within 48 hours. Three days later, he developed crushing chest pain, with arm tingling and jaw pain. He was triaged directly to the emergency room where he had troponins of greater than 11000 and T wave inversions on his EKG. Other diagnostic tests and labs showed normal heart anatomy and no early coronary artery disease. He was diagnosed with myopericarditis by cardiology. He was treated and recovered fully within 3 months. Discussion Using the WHO tool for adverse vaccine reactions, this case has a consistent causal relationship with vaccination. This is the eleventh case of myopericarditis reported to the Vaccine Adverse Effects Reporting system for the HPV vaccine. Conclusion Although rare, myopericarditis should be considered as a possible adverse effect from the human papillomavirus vaccine.

Challenges to Human Papillomavirus Vaccine Acceptability among Women in South India: An Exploratory Study

2021 ◽  
Author(s):  
Pooja Shah ◽  
Veena Shetty ◽  
Maithri Ganesh ◽  
Avinash K. Shetty
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Exploratory Study ◽  
Social Stigma ◽  
Hpv Vaccination ◽  
Scale Up ◽  
Vaccine Safety ◽  
Vaccine Uptake ◽  
Human Papillomavirus Vaccine ◽  
Barriers And Challenges

Cervical cancer is the second leading cause of cancer and one of the leading causes of cancer-related death in women in India. Human papillomavirus (HPV) vaccine uptake in India is low due to cost, low awareness of HPV, social stigma, and other factors. We assessed the awareness, attitudes, and beliefs regarding HPV and HPV vaccination and explored the barriers and challenges to HPV vaccine intent among women in Mangalore, India. An exploratory study was conducted using two focus group discussions (FGDs) and six in-depth one-on-one interviews. FGD-1 comprised nine women aged 18 to 26 years, and FGD-2 comprised seven women aged 27 to 45 years. The FGDs were recorded, transcribed, and analyzed using thematic content analysis. Themes identified were limited knowledge of HPV and vaccine, stigma associated with receiving HPV vaccine, vaccine safety concerns, and cost as a barrier to receiving vaccine. Participants expressed desire for physician and government recommendation of the HPV vaccine to validate vaccine intent. Contrasting themes between the two FGDs include support for vaccination at a younger age and lower perception of stigma and judgment in the 18- to 26-year-old group; however, participants in the 27- to 45-year-old group support vaccination at an older age and endorse greater fear of stigma and judgment associated with obtaining vaccination. Education regarding HPV-associated diseases and the HPV vaccine for the general public, physicians, and government officials in conjunction with lowering vaccine cost, improving vaccine access, and encouraging strong physician recommendations are key strategies to scale up HPV vaccine implementation in India.

Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink

Vaccine ◽  
2011 ◽  
Vol 29 (46) ◽  
pp. 8279-8284 ◽  
Author(s):  
Julianne Gee ◽  
Allison Naleway ◽  
Irene Shui ◽  
James Baggs ◽  
Ruihua Yin ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccine Safety ◽  
Human Papillomavirus Vaccine ◽  
Papillomavirus Vaccine

scholarly journals 962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S29-S29
Author(s):  
Julia Gargano ◽  
Rayleen Lewis ◽  
Hillary Hunt ◽  
Nancy McClung ◽  
Nancy M Bennett ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
The United States ◽  
Adenocarcinoma In Situ ◽  
Human Papillomavirus Vaccine ◽  
Impact Monitoring ◽  
Vaccine Impact ◽  
Race Ethnicity ◽  
Papillomavirus Vaccine

Abstract Background Since human papillomavirus (HPV) vaccine introduction in the United States in 2006, cervical pre-cancer incidence has declined in young women, but pre-cancer trends have not been reported by race/ethnicity. We evaluated trends in cervical pre-cancers from 2008 to 2016 in non-Hispanic (NH) white, NH black, NH Asian, and Hispanic women identified through active population-based surveillance in the 5-site Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT). Methods We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2–3 and adenocarcinoma in situ (CIN2+) cases aged 20–39 years. Annual CIN2+ rates per 100,000 women were calculated stratified by race/ethnicity in 5-year age groups, using multiple imputation to account for 10% missing race/ethnicity data. Rates were also calculated using estimated numbers screened for cervical cancer to control for known declines in screening. Trends, evaluated using JoinPoint software, are presented as average annual percentage changes (AAPC) with 95% confidence intervals (CI). Results A total of 18,222 CIN2+ cases (62% NH white, 16% NH black, 16% Hispanic, 6% Asian) were reported from 2008 to 2016. CIN2+ rates among 20–24 year-olds declined significantly in all groups: NH white, AAPC: −14.2 (95% CI: −16.3, −12.1); NH black, AAPC: −15.5 (−19.5, −11.4); Asian, AAPC: −14.8 (−20.5, −8.8); Hispanic, AAPC: −14.3 (−17.9, −10.5). In 25–29 year olds, a significant decline was observed for NH whites only (AAPC: −2.4, [−4.0, −0.8]). No declines were seen in 30–34 or 35–39 year olds. Among screened 20–24 year-olds, significant but smaller declines were observed (AAPC: −9.8 to −8.4); no declines were observed in screened 25–29 year olds or older groups. Conclusion In this evaluation of CIN2+ trends by race/ethnicity during the HPV vaccine era, the significant declines in 20–24 year olds across all groups, including among screened women, is consistent with equitable vaccine impact on CIN2+. Disclosures All Authors: No reported Disclosures.

Bioethics Human Papillomavirus and HPV Vaccine

2019 ◽  
Author(s):  
Christine Shanahan Davies
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Ethical Issues ◽  
Social Issues ◽  
Scientific Evidence ◽  
Ethical Question ◽  
Clinical Aspects ◽  
Human Papillomavirus Vaccine ◽  
Family Nurse Practitioner ◽  
Papillomavirus Vaccine

This paper will discuss what the Human Papillomavirus (HPV) is. Ethical questions posed are “Should the HPV (Human Papillomavirus) vaccine be required? If yes at what age and should it be required for both boys and girls? During the paper another ethical question that will be discussed is, “On what basis should parents be permitted to refuse and be exempt from the mandate”? An analysis of the Human papillomavirus will explain what is HPV, how it is passed between people, any symptoms that could occur, and information about treatment, vaccines, and prevention. The role and responsibilities of the Family Nurse Practitioner, clinical aspects, scientific evidence, conflicts, social issues, contextual facts and stakeholders will all be discussed. In addition bioethical principles autonomy, informed consent, beneficence, non-malfeasance, and justice will be discussed that are relevant and applicable to the ethical issues associated with the Human papillomavirus and HPV vaccine.

Attitudes about human papillomavirus vaccine in young women

2003 ◽  
Vol 14 (5) ◽  
pp. 300-306 ◽  
Author(s):  
Jessica A Kahn ◽  
Susan L Rosenthal ◽  
Tara Hamann ◽  
David I Bernstein
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Human Papillomavirus Vaccine ◽  
Chi Square ◽  
Positive Attitudes ◽  
Number Of Sexual Partners ◽  
Papillomavirus Vaccine ◽  
To Receive

Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women ( n=52, mean age 25 years, range 18-30 years, 35% Black/Non-Hispanic) completed a survey assessing knowledge, attitudes about HPV vaccination, and risk behaviours. Associations between attitudes and intention to receive the vaccine were assessed using Mann-Whitney U or chi-square tests. Subjects reported positive attitudes about receiving an HPV vaccine and high intention to receive the vaccine both for themselves and their daughters. Variables associated significantly with intention included knowledge ( P=0.004), personal beliefs about vaccination ( P=0.004), belief that others would approve of vaccination ( P=0.005), and higher number of sexual partners ( P=0.028). Information on attitudes about HPV vaccination and predictors of intention to receive a vaccine may guide immunization initiatives for young adults.

Sign in / Sign up

Export Citation Format

Share Document